Introduction pharmacodynamics, efficacy and side effect profiles. However, the magnitude and duration of first dose blood pressure Angiotensin converting enzyme (ACE) inhibition is an increasingly important therapy in cardiovascular medicine. In response may differ between ACE inhibitors. Regardless of the relatively low incidence of symptomatic first dose hypotenaddition to diuretic therapy these drugs now dominate the management of symptomatic chronic cardiac failure of sion (1-10% by variable trial evidence; [2, 3] ), it remains a concern for general practitioners when they prescribe ACE whatever origin and are becoming increasingly used in asymptomatic left ventricular dysfunction. Their role has inhibitors to this patient group [6] and may explain why ACE inhibitors are underutilised in heart failure [7] [8] [9] [10] . It is recently been extended into the management of myocardial infarction complicated by symptomatic or asymptomatic left clear that combination treatment with diuretics and ACE inhibition is important in this regard and hypoperfusion can ventricular dysfunction [1] [2] [3] [4] . There is now a wide range of agents available within this drug class [5] . Although each be damaging in some circumstances. Regardless of this the key concern is whether or not an individual clinician takes a decision to avoid ACE inhibitor therapy because of a rational
What little data are available in general practice suggests that years; height 1.67±0.9 m; weight 80±17 kg with an average duration of cardiac failure of 1.8±1.9 years (range this is unfortunately common [6, 10] .
Perindopril is an effective non thiol, ester prodrug ACE 0.2-6 years). The origin of cardiac failure in all instances was underlying previous myocardial infarction; seven patients inhibitor with a prolonged duration of effect dependent on the generation of an active diacid metabolite [11] . It had concomitant hypertension (29%) and one patient had concomitant valvular heart disease. Most patients were on increases exercise capacity in heart failure patients at doses substantially less than those used to achieve blood pressure loop diuretics which were held constant throughout the study (Table 1) . Concomitant drug therapy was as described lowering in patients with hypertension [12, 13] . One property of perindopril is the absence of a first dose fall in in Table 2 and remained constant for each individual for the duration of study. Patients on another ACE inhibitor (42%) systemic blood pressure in diuretic treated heart failure patients given a standard initial dose of 2 mg perindopril had this agent withdrawn for a minimum of 2 weeks prior to inclusion in the study. Treatment allocation was not after temporary diuretic withdrawal [14, 15] . The reason for this lack of first dose hypotension is unclear. It could be allocated on the basis of prior ACE inhibitor usage. All patients gave their written and informed consent to due to perindopril having balanced regional haemodynamic effects, an interaction between the parent ester prodrug, investigation prior to inclusion in the study. The protocol and procedures of the study were reviewed and passed perindopril and the active diacid metabolite ACE inhibitor perindoprilat [16] or it may simply be a dose dependent by the local research and ethics committee prior to investigation. effect not evident on chronic dosing.
In this study we have further explored the profile of perindopril during chronic dosing in heart failure patients. Firstly, we examined the first dose effects of perindopril.
Procedure Secondly, we investigated whether hypotension was avoided Following a screening visit during which demographic during chronic therapy with perindopril. Thirdly we characteristics, biochemistry, haematology and ECG in examined the renal effects of perindopril to assess whether addition to clinical history and physical examination were blood pressure changes influenced renal function, since renal documented, patients were assigned to randomized doubledysfunction is the other main concern when ACE inhibitors blind treatment in a parallel group design. Left ventricular are combined with chronic diuretic therapy.
dysfunction was documented and confirmed by transthoracic echocardiography (16 patients; calculated fractional shortenMethods ing 19±5%; left ventricular end diastolic diameter (6.4±0.7 cm) or by multiple uptake gated acquisition Patients radionuclide scan (15 patients; 31±3%). Prestudy symptomatic assessment assigned 12 patients to NYHA Grade II Twenty-four patients (17 male; 23 Caucasian) were recruited from our outpatient clinic. These subjects were aged 67±8 symptoms and 12 patients to NYHA Grade III. Prestudy Table 1 Diuretic therapy in patients completing the study (total daily dose, mg ). 
General safety and tolerability, baseline comparisons
Oral antidiabetic drugs 3 4 Patients were well matched in terms of demographic variables, pretreatment diuretic dose, heart failure classification and prestudy renal function and neurohormones clinical examination included a documented heart failure ( Tables 1, 2 and 3 ). There were no significant adverse effects score [17] which was elevated (mean 4.7±2.1).
and no treatment withdrawals. In addition to clinical examination, symptomatic assessment and graded heart failure scoring patients had supine
Biochemical effects of treatment ( Table 3 ) blood pressure and heart rate determined (Critikon Vital Signs Monitor, Tampa Bay, Florida) after the insertion of a There was no significant effect of active treatment on heparinised venous cannula and 30 min supine rest.
sodium, chloride, bicarbonate, protein, calcium, urea, Following triplicate blood pressure and heart rate determicreatinine, uric acid nor liver function tests (Table 3 ). There nations, blood samples were taken for the determination of was a small, statistically significant rise in serum potassium angiotensin converting enzyme [18] , aldosterone [19] , associated with perindopril treatment. Neither serum nor angiotensin peptides I and II [19] , atrial natriuretic factor erythrocyte magnesium was affected by active treatment. [19] , serum chemistry and haematology and measurement
There was sustained suppression of ACE activity in serum of serum and erythrocyte magnesium.
in those patients receiving perindopril compared to placebo. Patients were randomized to receive in addition to their concomitant therapy either perindopril 2 mg progressing to Neurohormones 4 mg daily from the second dose or matched placebo for the duration of study (8 
weeks). Following first dose
There was a statistically significant difference in the baseline levels of supine plasma aldosterone; ( placebo, administration patients remained under observation for a period of 6-8 h. Clinical review was conducted at 4 weeks 337.3±179 pg ml
, perindopril 635.8±357 pg ml −1 , P= 0.021). During the treatment phase plasma aldosterone was and 8 weeks during chronic dosing. In addition at baseline and following approximately 7 weeks treatment subjects had unaffected by placebo (375±306 pg ml −1 ) in contrast to the perindopril treated group where there was suppression renal function studies using isotope scintigraphic techniques to determine both glomerular filtration rate (GFR), effective from the elevated baseline (293.7±155 pg ml
, P=0.002). Baseline levels of angiotensin I (placebo, 33.7±13 pm; renal plasma flow (ERPF) and extracellular fluid volume (ECFV) [20] . perindopril 45.4±18 pm) and plasma angiotensin II ( placebo, 9.2±9.9; perindopril, 10.2±9 pm ) were not significantly supine or erect blood pressure or heart rate ( Table 4) There was a reduction in total heart failure score with perindopril treatment (4.9±5.3 baseline vs 3.4±1.9 at (20.7±39 pm) whereas chronic treatment with perindopril showed effective suppression of angiotensin II without conclusion) compared with placebo (3.7±2.3 at baseline vs 3.6±2.3 at conclusion). NYHA classification was not evidence of neurohormonal reactivation (3.6±2.7 pm ). Atrial natriuretic factor was similar in both groups prior significantly altered but all patients in the placebo group remained in the same NYHA class (7 Class II, 5 Class 3) to the study (placebo, 17.7±7.3 pm; perindopril 15.4±5.5 pm). Chronic treatment with placebo or perindowhereas in the perindopril treated group three patients shifted from Class III to Class II (five Class II, seven Class III pril had no impact on this hormone ( placebo, 17.5±4.7 pm; perindopril, 14.1±5.2 pm, P=0.51).
at baseline assessment became, eight Class II, four Class III at conclusion of treatment phase; P=0.106).
Blood pressure responses Renal function studies
There were no changes in electrolytes associated with active treatment with the exception of the small rise in potassium dose administration with a continuous observation period of 6 h in the supine position. Patients took their normal ( Table 3 ). The results of isotopic renal function studies conducted at baseline and at the end of the treatment phase diuretic dose on the day of attendance. Baseline systolic blood pressure was very similar in both treatment groups are illustrated in Table 5 . Overall there were no significant effects on calculated glomerular filtration rate, effective renal ( placebo, 137.5±18 mmHg; perindopril 137.5±15-mmHg ). There was a similar diurnal fall in blood pressure plasma flow or extracellular fluid volume. in both treatment groups which showed no significant difference between placebo (minimum value 115.3± Discussion 16 mmHg) or perindopril (117.8±17 mmHg ). In no patients were there any symptoms during the test dose phase
In the current study we have examined perindopril, a long acting ACE inhibitor used in the management of hypertenof the protocol and all patients went on to chronic dosing uneventfully. Blood pressures and heart rate were taken at sion and cardiac failure. The dose of perindopril advised for heart failure management is effectively half that employed regular intervals in triplicate during the study after 30 min supine rest. Erect blood pressure was taken at 1, 3 and 5 min in its role as an antihypertensive drug [13] . Perindopril improves exercise tolerance in heart failure patients at this thereafter. Only baseline and 8 week pressures are presented in Table 4 . During chronic therapy with placebo or lower dose [12] . Mortality data in stable chronic heart failure have not been published for this drug. As yet there are no perindopril there was no significant difference in the blood pressure profile between the two treatment arms for either data to suggest that effects on exercise tolerance will occur at different doses from effects on mortality but the dose of strated irrespective of dose and in most instances demonstrable blood pressure fall is routine [26] . A hypothesis to any ACE inhibitor used in CHF continues to be surrounded by controversy.
explain this failure of first dose hypotension with perindopril has been put forward based on ester diacid interaction with In this small controlled double-blind parallel group study, symptoms were not a primary endpoint but there was an the different components of perindopril [11, 27] . In the present study chronic dosing with perindopril has revealed appreciable effect on heart failure score which would support symptomatic efficacy at this dose. We also found non no additional effect on supine or erect blood pressure over and above placebo. As a proportion of the patients in our significant changes in NYHA class to support this notion. In addition, there were no biochemical adverse events in controlled study (42%) had already received an ACE inhibitor as part of their ongoing clinical care, without either treatment group.
ACE inhibitors are proven to be of major benefit in heart symptoms, then we may have unwittingly selected out those prone to symptomatic hypotension. This may be relevant failure but recently it has been noted that some patients exhibit 'neurohormonal escape' during chronic ACEI to the occurrence of postural dizziness in individual patients which is accepted as a troublesome albeit infrequent therapy. Reactive hyperreninaemia is thought to cause elevation of angiotensin I with subsequent reappearance of complication of chronic ACE inhibitor therapy in heart failure [3] . However this does not influence the measured near normal if not elevated levels of circulating angiotensin II despite chronic ACEI therapy [21, 22] . Another explanation blood pressure response to treatment nor the fact that the relationship between measured blood pressure and symptoms for the reappearance of normal angiotensin II levels is that patients may simply fail to comply with ACE inhibitor is frequently obscure on an individual patient basis. Nevertheless, the lack of hypotension in a small study (n= therapy. Regardless of the mechanism it is clear from population studies that those CHF patients who fail to 12) does not rule out a population frequency of almost 3% (rule of threes 100/3n×100%). maintain angiotensin II suppression despite ACE inhibitor therapy have a higher level of morbidity and mortality [22] .
Whatever the real frequency of hypotension in diuretic treated heart failure patients given an ACEI, and this appears In the present study not only was there the expected suppression of serum ACE on chronic dosing with perindoplow yet variable in controlled trials, it remains a matter of concern that fear of first dose hypotension is used as a ril, but effective suppression of angiotensin II was also maintained in all patients during the 2 month treatment common reason for physicians to withold ACEI treatment especially in elderly heart failure patients [6] [7] [8] . Current period. This suggests that neurohormonal escape does not occur with low dose perindopril. Alternatively poor comevidence for the UK suggests that only 17% of heart failure patients actually receive an ACE inhibitor [8] . pliance rather than hyperreninaemia may be the real reason for angiotensin II 'reactivation' when it occurs and AII The patients studied in this report started with normal renal electrolytes although their age, concomitant loop reactivation did not occur in this trial because patient compliance is typically better during clinical trials. Another diuretic use and baseline renal perfusion assessment (see Table 5 ) are accepted to predispose to adverse effects on possible, but unlikely explanation is that the 2 month treatment period was too short for angiotensin II reactivation renal perfusion following the addition of an ACE inhibitor to a loop diuretic [29] . We found no significant changes in to be seen.
At the doses of perindopril empirically selected for cardiac renal function following perindopril. In individual patients ACE inhibitors may cause a fall in renal function [29] . For failure patients there is no first dose blood pressure response when this drug is administered following temporary diuretic the most part this relates specifically to the combination of a loop diuretic and an ACE inhibitor where the angiotensin II withdrawal [14, 15] . In the present study there was no diuretic withdrawal employed but again the 2 mg first dose mediated efferent arteriolar tone, which was maintaining glomerular filtration, is withdrawn. It has been suggested of perindopril had no significant effect on blood pressure compared with placebo. Regardless of the mechanisms that these renal responses to ACE inhibition support the use of short acting agents where haemodynamic and neurohorinvolved, this is a positive safety feature for the initiation of therapy in ambulant patients. This property differentiates monal effects last only a matter of hours [30] . By contrast, long acting drugs whose impact is sustained from one dose perindopril from other ACE inhibitors where in a few cases marked falls in blood pressure [23-25] have been demoninterval into the next might be more likely to produce renal investigation and treatment of patients with heart failure. Br dysfunction [30, 31] . In the present study, perindopril, Heart J 1994; 71: 584-587.
which has a protracted duration of effect, had no significant 
